September 23, 2020

Johnson and Johnson $JNJ Stock Options Bullish On Phase 3 Trial of COVID-19 Vaccine

JNJ stock moved slightly higher on a big down day for markets on September 23, 2020. Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal,

Biotechnology

Coronavirus

September 23, 2020

Athersys $ATHX Stock Up On Treatment of Acute Respiratory Distress Syndrome

ATHX stock rose in pre-market trading after the company announced an update on its product that treats acute respiratory distress syndrome. Athersys, Inc., a leading regenerative medicine company in late-stage

Biotechnology

Coronavirus

September 23, 2020

MediciNova $MNOV Stock Up On Intranasal COVID-19 Vaccine

MNOV stock rose in pre-market trading on September 23, 2020, after the company announced its intranasal SARS-CoV-2 vaccine prototype for COVID-19, using BC-PIV technology, successfully induced systemic serum IgG and

Biotechnology

September 21, 2020

Hoth Therapeutics $HOTH Stock Up On Mobile Covid Testing Device

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement ("SRA") with the George Washington University ("GW") relating to the development

Biotechnology

September 21, 2020

$AMPE Ampio Pharmaceuticals Up On FDA IND and Clinical Trial

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") announces the receipt of an Investigational New Drug ("IND") from the U.S. Food and Drug Administration ("FDA"), allowing the Company to proceed with clinical trials

Biotechnology

September 21, 2020

$LEGN Legend Biotech Down With CEO Under Surveillance in China

Shares of Legend Biotech are moving lower after the company announced that its Dr. Fangliang Zhang is presently under residential surveillance by the People's Republic of China law enforcement. Legend appointed

Biotechnology

September 20, 2020

$LLY Eli Lilly says Verzenio Reduced Cancer Recurrence by Shocking 25%

Eli Lilly announced Verzenio in combination with standard adjuvant endocrine therapy "significantly" decreased the risk of breast cancer recurrence by 25% compared to standard adjuvant ET alone for people with

Biotechnology

September 20, 2020

$AZN $MRK LYNPARZA Reduced Death by 31% for Men With Castration Resistant Prostate Cancer

AstraZeneca (AZN) and Merck (MRK), known as MSD outside the United States and Canada, today announced final results from the Phase 3 PROfound trial which showed LYNPARZA demonstrated a statistically

Biotechnology

September 19, 2020

$BMY $EXEL Opdivo, Cabometyx Shows Significant Survival in Patients with Advanced Renal Cell Carcinoma

Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced the first presentation of results from the pivotal Phase 3 CheckMate -9ER trial, in which Opdivo® (nivolumab) in

Stock Trading

September 19, 2020

$AZN TAGRISSO Reduced Disease Recurrence in the Brain by Shocking 82%

Results from a prespecified exploratory analysis of the positive ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a clinically meaningful improvement in central nervous system (CNS) disease-free survival (DFS)

« Older Articles